Matches in Wikidata for { <http://www.wikidata.org/entity/Q80357289> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- Q80357289 description "article scientifique publié en 2007" @default.
- Q80357289 description "artículu científicu espublizáu n'abril de 2007" @default.
- Q80357289 description "im April 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q80357289 description "scientific article published on 29 April 2007" @default.
- Q80357289 description "wetenschappelijk artikel" @default.
- Q80357289 description "наукова стаття, опублікована у квітні 2007" @default.
- Q80357289 name "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 name "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 type Item @default.
- Q80357289 label "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 label "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 prefLabel "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 prefLabel "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 P1433 Q80357289-F11575EC-CEE2-4E93-BFEC-0756EDAB8551 @default.
- Q80357289 P1476 Q80357289-7161E7E1-0A91-4759-8C69-40321026FB2E @default.
- Q80357289 P2093 Q80357289-2AD0C7D3-6C1A-46C7-A50E-595EF4B9935E @default.
- Q80357289 P2093 Q80357289-4DB41617-64BF-4A1E-B88E-9E196E5FBC38 @default.
- Q80357289 P2093 Q80357289-56747D70-8FF7-45AE-A264-A0DC02F52E06 @default.
- Q80357289 P2093 Q80357289-63D4B6A7-527A-4981-9C79-8D261AE83173 @default.
- Q80357289 P2093 Q80357289-72E23104-A627-4167-9C1B-A5FBCF9AFEC1 @default.
- Q80357289 P2093 Q80357289-86372B54-0E86-4726-8B16-76B0A1197FB6 @default.
- Q80357289 P2093 Q80357289-8BCEA765-B292-49C9-A7A7-D4721A7EECB3 @default.
- Q80357289 P2093 Q80357289-8BF135CC-F46F-413F-9447-F7BB0EA06DF5 @default.
- Q80357289 P2093 Q80357289-9DA463B1-FC87-4E2C-9245-1602FBC1228B @default.
- Q80357289 P2093 Q80357289-C1EEE279-C621-4E6D-8031-7148A0367DB6 @default.
- Q80357289 P2093 Q80357289-CB2775AE-742F-4168-BD7B-96F45F447B37 @default.
- Q80357289 P2093 Q80357289-D975AF3F-C8D2-4F57-99B0-B6CEA7B3B738 @default.
- Q80357289 P2093 Q80357289-DC04B4C2-6A74-4A0E-BCAE-129A59E0D01D @default.
- Q80357289 P2093 Q80357289-DDE6E9C3-1A6F-4338-8937-CD8951E0EA1E @default.
- Q80357289 P2093 Q80357289-E0429DDA-AE03-4364-A3E6-18E41A9C5688 @default.
- Q80357289 P2093 Q80357289-E38A580F-2030-4EC9-BE6E-150A44B069D2 @default.
- Q80357289 P2093 Q80357289-F2D1B26D-4F8F-4BC3-97AE-6F94461C58E3 @default.
- Q80357289 P304 Q80357289-08F5F396-F7DC-4EF6-BEB2-F056B998314A @default.
- Q80357289 P31 Q80357289-8307AF6C-AF75-46FC-B354-D1F012B2C8EC @default.
- Q80357289 P356 Q80357289-D47D2E5B-29AC-474A-A940-BD6D6CCF1881 @default.
- Q80357289 P433 Q80357289-876184CF-4773-4767-8CC8-3D9040CDCF5A @default.
- Q80357289 P478 Q80357289-F57106A4-FCEA-472A-816A-5909E85461A4 @default.
- Q80357289 P50 Q80357289-77B3FFB7-069C-4A5A-A881-BD0286E7DE3A @default.
- Q80357289 P577 Q80357289-9CB261CC-BC1E-46C8-A021-D7E0543D42E3 @default.
- Q80357289 P698 Q80357289-7F7D4454-B603-4DA2-9354-D9B91622E3EA @default.
- Q80357289 P921 Q80357289-198D0490-F363-4D09-BE9C-8CBC72C0FAA7 @default.
- Q80357289 P356 J.BMCL.2007.04.087 @default.
- Q80357289 P698 17513109 @default.
- Q80357289 P1433 Q2709483 @default.
- Q80357289 P1476 "Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series" @default.
- Q80357289 P2093 "Annapurna Pendri" @default.
- Q80357289 P2093 "Bruce A Ellsworth" @default.
- Q80357289 P2093 "Chongqing Sun" @default.
- Q80357289 P2093 "Kamelia Behnia" @default.
- Q80357289 P2093 "Kenneth E Carlson" @default.
- Q80357289 P2093 "Liya Kang" @default.
- Q80357289 P2093 "Mary Ann Pelleymounter" @default.
- Q80357289 P2093 "Mary Jane Cullen" @default.
- Q80357289 P2093 "Neil T Burford" @default.
- Q80357289 P2093 "Qi Huang" @default.
- Q80357289 P2093 "Rose A Baska" @default.
- Q80357289 P2093 "Susan Johnghar" @default.
- Q80357289 P2093 "William N Washburn" @default.
- Q80357289 P2093 "William R Ewing" @default.
- Q80357289 P2093 "Yeheng Zhu" @default.
- Q80357289 P2093 "Yifan Yang" @default.
- Q80357289 P2093 "Ying Wang" @default.
- Q80357289 P304 "3978-3982" @default.
- Q80357289 P31 Q13442814 @default.
- Q80357289 P356 "10.1016/J.BMCL.2007.04.087" @default.
- Q80357289 P433 "14" @default.
- Q80357289 P478 "17" @default.
- Q80357289 P50 Q52147370 @default.
- Q80357289 P577 "2007-04-29T00:00:00Z" @default.
- Q80357289 P698 "17513109" @default.
- Q80357289 P921 Q417571 @default.